Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

News Industry News

Two-year data shows trend towards lower target vessel failure with Indian stent Supraflex vs. Xience stent from Abbott

October 09, 2019

News Conference News TCT 2019

IVUS-XPL at 5 Years Shows Durability of Imaging Guidance in PCI

Caitlin E. Cox

October 08, 2019

News Conference News TCT 2019

Ultrathin-Strut Orsiro Stent as Good as BioMatrix: BIODEGRADE

Michael O'Riordan

September 30, 2019

News Conference News TCT 2019

Leave It Be: PCI for Stable CAD Before or With TAVR Does Not Lower Mortality Risk

Michael O'Riordan

September 29, 2019

News Conference News ESC 2019

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

Caitlin E. Cox

September 10, 2019

News Conference News ESC 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

Todd Neale

September 03, 2019

News Conference News ESC 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Michael O'Riordan

September 01, 2019

News Industry News

SINOMED® Concludes Enrollment of the PIONEER III Randomized, Pivotal Study of the BuMA Supreme® Coronary Drug-Eluting Stent

July 23, 2019

News Industry News

SMT Announces CE* Mark for the Most Deliverable Stent Supraflex Cruz

July 11, 2019

News Conference News EuroPCR 2019

Daring to Dream: New BRS Data Hint at Low MACE Rates at 2 and 3 Years

Michael O'Riordan

May 27, 2019

News Conference News EuroPCR 2019

Firehawk Stent Still Holds Up Well to Xience at 2 Years: TARGET All Comers

Caitlin E. Cox

May 23, 2019

Presentation EuroPCR 2019

3-year clinical outcome following treatment with thin, very thin or ultrathin strut drug-eluting stents in small coronary vessels in BIO-RESORT

Presenter: Clemens von Birgelen

May 21, 2019

News Conference News EuroPCR 2019

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

Shelley Wood

May 16, 2019

News Daily News

Registries Point to Lower Risk of Death With CABG vs PCI in Multivessel CAD

Michael O'Riordan

May 02, 2019

News Daily News

Three Years On, Absorb BVS Still Doesn’t Improve Myocardial Blood Flow

Michael O'Riordan

April 30, 2019

News Daily News

Mortality Data ‘Inadvertently Omitted’ From IN.PACT Analysis of Paclitaxel-Coated Balloons

L.A. McKeown

February 19, 2019

Presentation JIM 2019

Unmet Clinical Needs With Current Drug-Eluting Stents

Presenter: Davide Capodanno

February 14, 2019

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

L.A. McKeown

January 23, 2019

News Daily News

Slight Advantage for DES Over DCB for In-Stent Restenosis: Updated Meta-analysis

Todd Neale

January 15, 2019

CME

Advertisement

Two-year data shows trend towards lower target vessel failure with Indian stent Supraflex vs. Xience stent from Abbott

IVUS-XPL at 5 Years Shows Durability of Imaging Guidance in PCI

Ultrathin-Strut Orsiro Stent as Good as BioMatrix: BIODEGRADE

Leave It Be: PCI for Stable CAD Before or With TAVR Does Not Lower Mortality Risk

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

SINOMED® Concludes Enrollment of the PIONEER III Randomized, Pivotal Study of the BuMA Supreme® Coronary Drug-Eluting Stent

SMT Announces CE* Mark for the Most Deliverable Stent Supraflex Cruz

Daring to Dream: New BRS Data Hint at Low MACE Rates at 2 and 3 Years

Firehawk Stent Still Holds Up Well to Xience at 2 Years: TARGET All Comers

3-year clinical outcome following treatment with thin, very thin or ultrathin strut drug-eluting stents in small coronary vessels in BIO-RESORT

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

Registries Point to Lower Risk of Death With CABG vs PCI in Multivessel CAD

Three Years On, Absorb BVS Still Doesn’t Improve Myocardial Blood Flow

Mortality Data ‘Inadvertently Omitted’ From IN.PACT Analysis of Paclitaxel-Coated Balloons

Unmet Clinical Needs With Current Drug-Eluting Stents

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

Slight Advantage for DES Over DCB for In-Stent Restenosis: Updated Meta-analysis

Updates on Onyx ONE

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content